Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to ensure that the National Institute for Health and Care Excellence and the Scottish Intercollegiate Guidelines Network to work together to review and update clinical guidelines on type 1 diabetes and eating disorders, including guidance on diagnosis and treatment.

The National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have a shared interest to improve quality of care for patients through the development of clinical guidelines. SIGN works together with NICE in several areas, including identifying and undertaking joint initiatives to reduce duplication of effort and improve efficiency in their respective guideline development programmes and providing joint solutions to issues affecting guideline development in the United Kingdom.

NICE has published guidelines on the diagnosis and management of Type 1 diabetes in adults and in children, namely NG17 and NG18. Both include recommendations on dietary management and NG17 has recommendations on managing complications, including eating disorders. NICE has also published a guideline on the recognition and treatment of eating disorders, namely NG69. This guideline includes recommendations for people with diabetes and physical and mental health comorbidities, including eating disorders. Copies of guidelines NG17 and NG69 are attached.

NICE intends to carry out focussed updates to all diabetes guidance to take account of changes in insulin availability but has no current plans for further updates to NG17 and NG18, either alone or in collaboration with SIGN. NICE takes a proactive approach to surveillance, monitoring for changes in the evidence base that may impact on its recommendations. Topics for new or updated guidance are considered through the NICE prioritisation process. Decisions as to whether NICE will create new, or update existing, guidance are overseen by an integrated, cross-organisational prioritisation board, chaired by NICE’s chief medical officer.